U.S. Markets open in 9 hrs 11 mins

The Cytosorbents (NASDAQ:CTSO) Share Price Is Down 46% So Some Shareholders Are Getting Worried

Simply Wall St

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That downside risk was realized by Cytosorbents Corporation (NASDAQ:CTSO) shareholders over the last year, as the share price declined 46%. That's disappointing when you consider the market returned 6.2%. On the bright side, the stock is actually up 44% in the last three years. It's down 1.4% in the last seven days.

View our latest analysis for Cytosorbents

Given that Cytosorbents didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Cytosorbents grew its revenue by 34% over the last year. That's definitely a respectable growth rate. Unfortunately that wasn't good enough to stop the share price dropping 46%. You might even wonder if the share price was previously over-hyped. But if revenue keeps growing, then at a certain point the share price would likely follow.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

NasdaqCM:CTSO Income Statement, August 1st 2019

This free interactive report on Cytosorbents's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Investors in Cytosorbents had a tough year, with a total loss of 46%, against a market gain of about 6.2%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 1.9%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

We will like Cytosorbents better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.